Mechanical Unloading Aggravates Bone Destruction and Tumor Expansion in Myeloma

Overview

Journal Haematologica

Specialty Hematology

Date 2021 Nov 18

PMID 34788982

Citations 2

Authors

Kotaro Tanimoto

Masahiro Hiasa

Hirofumi Tenshin

Jumpei Teramachi

Asuka Oda

Takeshi Harada

Yoshiki Higa

Kimiko Sogabe

Masahiro Oura

Ryohei Sumitani

Tomoyo Hara

Itsuro Endo

Toshio Matsumoto

Eiji Tanaka

Masahiro Abe

Affiliations

Soon will be listed here.

Citing Articles

Myeloma cell-derived CXCL7 facilitates proliferation of tumor cells and occurrence of osteolytic lesions through JAK/STAT3 pathway.

Wang Y, Lan T, Zhang Q, Zhou C, Liu P Cell Death Dis. 2025; 16(1):74.

PMID: 39915476 PMC: 11802855. DOI: 10.1038/s41419-025-07413-6.

Myeloma bone disease: pathogenesis and management in the era of new anti-myeloma agents.

Teramachi J, Miki H, Nakamura S, Hiasa M, Harada T, Abe M J Bone Miner Metab. 2023; 41(3):388-403.

PMID: 36856824 PMC: 9975874. DOI: 10.1007/s00774-023-01403-4.

TAK1-inhibitors did not reduce disease burden in a Vκ*MYC model of multiple myeloma.

Haland E, Moen I, Vandsemb E, Starheim K BMC Res Notes. 2022; 15(1):352.

PMID: 36435864 PMC: 9701378. DOI: 10.1186/s13104-022-06237-3.

References

Amblard D, Lafage-Proust M, Laib A, Thomas T, Ruegsegger P, Alexandre C . Tail suspension induces bone loss in skeletally mature mice in the C57BL/6J strain but not in the C3H/HeJ strain. J Bone Miner Res. 2003; 18(3):561-9. DOI: 10.1359/jbmr.2003.18.3.561. View

Terpos E, Berenson J, Raje N, Roodman G . Management of bone disease in multiple myeloma. Expert Rev Hematol. 2014; 7(1):113-25. DOI: 10.1586/17474086.2013.874943. View

Nakashima T, Hayashi M, Takayanagi H . New insights into osteoclastogenic signaling mechanisms. Trends Endocrinol Metab. 2012; 23(11):582-90. DOI: 10.1016/j.tem.2012.05.005. View

Friedman M, Zhang Y, Wayne J, Farber C, Donahue H . Single limb immobilization model for bone loss from unloading. J Biomech. 2018; 83:181-189. DOI: 10.1016/j.jbiomech.2018.11.049. View

Polyzos S, Anastasilakis A, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E . Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide. Osteoporos Int. 2011; 23(3):1171-6. DOI: 10.1007/s00198-010-1525-6. View

Pagnotti G, Chan M, Adler B, Shroyer K, Rubin J, Bain S . Low intensity vibration mitigates tumor progression and protects bone quantity and quality in a murine model of myeloma. Bone. 2016; 90:69-79. PMC: 4970889. DOI: 10.1016/j.bone.2016.05.014. View

Lawson M, McDonald M, Kovacic N, Khoo W, Terry R, Down J . Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche. Nat Commun. 2015; 6:8983. PMC: 4686867. DOI: 10.1038/ncomms9983. View

Miyazaki T, Zhao Z, Ichihara Y, Yoshino D, Imamura T, Sawada K . Mechanical regulation of bone homeostasis through p130Cas-mediated alleviation of NF-κB activity. Sci Adv. 2019; 5(9):eaau7802. PMC: 6760935. DOI: 10.1126/sciadv.aau7802. View

Asano J, Nakano A, Oda A, Amou H, Hiasa M, Takeuchi K . The serine/threonine kinase Pim-2 is a novel anti-apoptotic mediator in myeloma cells. Leukemia. 2011; 25(7):1182-8. DOI: 10.1038/leu.2011.60. View

10.

Hiasa M, Teramachi J, Oda A, Amachi R, Harada T, Nakamura S . Pim-2 kinase is an important target of treatment for tumor progression and bone loss in myeloma. Leukemia. 2014; 29(1):207-17. DOI: 10.1038/leu.2014.147. View

11.

Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T . Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104(8):2484-91. DOI: 10.1182/blood-2003-11-3839. View

12.

Teramachi J, Tenshin H, Hiasa M, Oda A, Bat-Erdene A, Harada T . TAK1 is a pivotal therapeutic target for tumor progression and bone destruction in myeloma. Haematologica. 2020; 106(5):1401-1413. PMC: 8094086. DOI: 10.3324/haematol.2019.234476. View

13.

Rummler M, Ziouti F, Bouchard A, Brandl A, Duda G, Bogen B . Mechanical loading prevents bone destruction and exerts anti-tumor effects in the MOPC315.BM.Luc model of myeloma bone disease. Acta Biomater. 2020; 119:247-258. DOI: 10.1016/j.actbio.2020.10.041. View

14.

Robling A, Niziolek P, Baldridge L, Condon K, Allen M, Alam I . Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J Biol Chem. 2007; 283(9):5866-75. DOI: 10.1074/jbc.M705092200. View

15.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E . Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy. Int J Cancer. 2011; 131(6):1466-71. DOI: 10.1002/ijc.27342. View